Healthcare
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(GZPHF)
Live Price
Offline$2.34
+0.00% today
1Y Change
+6.36%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $36.82B
- Revenue Growth
- +0.6%
- EPS Growth
- +4.6%
- Dividend Yield
- 3.5%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) is a Healthcare stock with a market cap of $36.82B and listed on OTC. The stock last traded around $2.34 and up 6.4% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +0.6%, EPS growth of +4.6%, a dividend yield of 3.5%. What stands out right now is revenue +0.6%, EPS +4.6%, free cash flow -141.2% with operating margin 4.1% and ROIC 4.0%. The dividend matters to the case here, with a current yield around 3.5%. Valuation is more restrained than many high-expectation growth names at P/E 12.5 and price/sales 0.5. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines GZPHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.6% vs +7.6% peer median
Operating Margin
Below sector median
+4.1% vs +19.4% peer median
P/E
Below sector median
12.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 28, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +0.6% and EPS at +4.6%, with operating margin around 4.1%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.5%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 28, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 20, 2026 | -145.4% | +0.0% | +0.0% | +0.0% |
2025 Oct 28, 2025 | +13.5% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
GZPHF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GZPHF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GZPHF Max Drawdown
-10.08%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GZPHF and SPY.
Company Overview
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Other OTC
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2021, it had 154 retail chain pharmacy outlets, which included 22 Cai Zhi Lin pharmacy outlets, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy outlets, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd outlets, as well as 22 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.
- Leadership
- Hong Li
- IPO Date
- Jan 5, 2010
- Employees
- 28.1k
- Street Address
- 45 Sha Mian North Street
- Mailing
- Guangzhou, 510130
- Region
- Guangzhou, CN
- Reporting Currency
- USD
- Investor Line
- 86 20 6628 1218
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 12.5
- EV/EBITDA
- 12.9
- Price/Sales
- 0.5
- Price/Book
- 0.9
Growth
- Revenue
- +0.6%
- EPS
- +4.6%
- Free Cash Flow
- -141.2%
Profitability
- Gross Margin
- 16.0%
- Operating Margin
- 4.1%
- Net Margin
- 3.8%
- ROE
- 7.7%
- ROIC
- 4.0%
Balance Sheet
- Debt/Equity
- 0.59
- Current Ratio
- 1.60
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.